UN NCCN guidelines The US NCCN Clinical Practice Guidelines: Hepatobiliary Tumor (2018.V1) was updated on February 15, 2018. The latest version of the guideline uses proton therapy as one of the standard treatments for head and n..
Because liver cancer has many types, strong inheritance, and easy recurrence, identifying biomarkers that can predict disease progression is a key goal in fighting liver cancer.Recently, researchers have developed a method to iden..
Liver cancerIn the past two decades, the number of deaths caused by liver cancer has increased by 80%, becoming one of the fastest growing causes of cancer deaths worldwide.Liver cancer mortality ranks second in the world for canc..
Liver cancer backgroundA local man in Cincinnati unfortunately suffered from a rare form of liver cancer. The doctor told him that he only had a life span of 3-6 months. However, because of a cancer treatment team at the Universit..
A Duke University study has shown that metastatic cancer cells can regulate the metabolic function to reproduce in new organs. Cells derived from colorectal cancer have changed their metabolic habits, making full use of fructose ..
A study showed that drinking more coffee can reduce the risk of developing the most common primary liver cancer. Researchers from the University of Southampton and the University of Edinburgh found that the more coffee you drink,..
In the past two decades, the number of deaths caused by liver cancer has increased by 80%, becoming one of the fastest growing causes of cancer deaths worldwide. According to the "Global Burden of Disease Study", 830,000 people d..
For patients with unresectable hepatocellular carcinoma (HCC), the first-line treatment options are limited, including local ablation, arterial-directed therapy, or external radiation therapy or chemotherapy. Sorafenib (Dogime) ..
At the end of 2015, science research claimed that high doses of vitamin C (about the equivalent of 300 oranges) can effectively kill colon cancer cells that carry a common carcinogenic mutation (KRAS and BRAF).In March 2017, "Canc..
At the 2018 Gastrointestinal Cancer Symposium, the results of the Phase III CELESTIAL trial showed that compared with placebo, carbotinib can improve the overall survival (OS) of previously treated patients with advanced liver ca..